FinBoss.io
CSEN
  • Crypto prices
  • Liquidation War
  • Crypto tools
  • Bitcoin on-chain
  • US macro
  • US stocks
    • Largest US stocks
    • Stock screener
    • Earnings calendar
    • Insider trading
    • Market heatmap
  • Markets
  • Tools
  • Guides
  • FinBot
FinBoss.io
Crypto prices
Liquidation War
Crypto tools
Altcoin Season Index
Big players (on-chain)
Bitcoin halving countdown
Bear market radar
Bitcoin on-chain
Hashrate
Mining difficulty
Mining pools
Mempool and fees
On-chain activity
MVRV and NUPL
SOPR
Holders
Supply in profit
Rainbow Chart
Fair value
Pi Cycle Top
US macro
FedWatch
Interest rates
Treasury yields
Inflation
Liquidity and Bitcoin
Business cycle
US stocks
Largest US stocks
Stock screener
Earnings calendar
Insider trading
Market heatmap
Markets
Stock indices
Commodities
Forex rates
Bear market radar
Famous investors' portfolios
Tools
Dashboards
Investor dashboardTrader dashboardBeginner dashboard
Calculators
Compound interestDCA calculatorDrawdown recovery
Compare
BrokersCrypto exchanges
Přehled sekce Tools →
Guides
FinBot
CSEN
Home
Stocks
Prestige Consmr Healthcare I
PB

Prestige Consmr Healthcare I

PBHNASDAQ

Stock · Data from SEC EDGAR 13F · Held by 6 of 87 tracked investors

$47.39
▼ 1.58%
Famous investorshold 6buying 0selling 0
Price (USD)
$47.39
Market cap
$2.2B
P/E ratio
13.3
Tracked investors holding
6 of 87
Next earnings
5 Nov 2026

Prestige Consmr Healthcare I at a glance

An overview of the financial statements, in plain language. Switch to the advanced view for charts.

FinBoss score
62out of 100
  • Valuation88
  • Growth36
  • Profitability76
  • Quality71
  • Debt25
  • Stability76
In its favour
  • ✓Out of 100 USD of revenue, 16 USD is left as net profit.
  • ✓The stock is cheaper: you pay 13.3 USD for 1 USD of annual earnings.
  • ✓The analysts' average target is 43% above the price.
What to watch
  • !Net debt is high: at the current free cash flow it would take 13.4 years to repay.
  • !Revenue fell 1.2% a year over 3 years.

The score describes the quality and the past of the company based on its statements (the FinBoss model, indicative). A high score is not a buy signal and a low one is not a sell signal. Data source: Yahoo Finance, prices and statements in USD.

Is the stock expensive?

Fairly cheap

For 1 USD of annual earnings you pay 13.3 USD. Based on next year's estimates 9.3 USD.

P/E
13.3×
P/S
2.0×
EV/EBITDA
13.0×

Is the company growing?

Shrinking
23
24
25
26

Revenue over 3 years grew -1.2% a year. Last year 6.5%.

Does it make money?

Good

Revenue and net profit (USD B)

Margins (% of revenue)

Free cash flow and capex (USD B)

Cash and debt (USD B)

Earnings per share (EPS, USD)

Latest quarters (USD B)

Chart PBH

Insider purchases

last 90 days, SEC Form 4
Loading insider trades…

Which investors hold this stock

6
JR
John Rogers
Ariel Investments
2.29%$230,143,970▲ +13.9%
LA
Lee Ainslie
Maverick Capital
0.02%$2,409,588New position
RD
Ray Dalio
Bridgewater Associates
0.01%$2,193,659New position
JG
Joel Greenblatt
Gotham Asset Management
0%$1,308,954▲ +93.4%
KF
Ken Fisher
Fisher Investments
0%$11,698,136▼ -1.5%
Ns
Norský státní fond
Norges Bank
0%$3,542,745New position

Frequently asked questions

How much is Prestige Consmr Healthcare I (PBH) stock?

Prestige Consmr Healthcare I shares trade at $47.39, -1.58% over the last trading day. The price is delayed.

What is the market cap of Prestige Consmr Healthcare I?

The market cap of Prestige Consmr Healthcare I is about $2.2B and its price-to-earnings ratio (P/E) is 13.3.

Which big investors hold Prestige Consmr Healthcare I?

According to the latest 13F filings, 6 of 87 tracked investors hold Prestige Consmr Healthcare I, for example John Rogers, Lee Ainslie, Ray Dalio.

When will Prestige Consmr Healthcare I report its next results?

The next earnings report of Prestige Consmr Healthcare I is expected on 5 Nov 2026.

Source: SEC EDGAR 13F-HR (quarterly filings). The data is indicative and is not investment advice.

© 2026 FinBoss.io. All rights reserved.

How we make moneyTerms of usePrivacy policyCookie policy

Disclaimer: the information on this site is for general information only and is not investment or financial advice. Investing involves risk, and cryptocurrencies are especially volatile. Past performance does not guarantee future results. Some links are affiliate links and are marked as ads.

  • Cost of sales 45
  • Research 0.0
  • Operations and selling 26.3
  • Taxes and other 10.9
  • Net profit 17.5

Out of 100 USD of revenue, 17.5 USD is left as net profit.

Is it financially healthy?

Watch the debt
Cash
89M USD
Debt
2.1B USD
Free CF
148M USD

It could repay its net debt from free cash flow in 13.4 years.

Does it pay a dividend?

No dividend

The company pays no dividend. It reinvests the money or holds it.

What do analysts expect?

none
Average target
67.80 USD
Vs price
+43%

5 analysts. Their opinion is not a recommendation by FinBoss.io.

Which big investors hold it?

6 of 87

Among the tracked investors, John Rogers, Lee Ainslie, Ray Dalio and others hold the stock according to 13F filings.

Ratios

P/E
13.3×
Forward P/E
9.3×
P/B
1.2×
P/S
2.0×
PEG
1.52
EV/EBITDA
13.0×
Gross margin
54.8%
Operating margin
20.8%
Net margin
15.6%
ROE
9.1%
ROA
4.6%
Debt / equity
1.1×
Current ratio
3.2×
Revenue growth
6.5%
Earnings growth
-35.8%
Beta
0.34
Dividend
0.00%
Payout ratio
0%